search

Active clinical trials for "Carcinoma"

Results 21-30 of 7825

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors...

Non-small Cell Lung CancerHead and Neck Squamous Cell Carcinoma4 more

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.

Recruiting27 enrollment criteria

Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical...

Adrenocortical Carcinoma

This is a prospective randomized, double blind, placebo controlled phase II study planned in patients with advanced ACC. The study will be conducted at ASST Spedali Civili Hospital and University of Brescia in Brescia.

Recruiting16 enrollment criteria

Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

To evaluate the efficacy and safety of lenvatinib, tislelizumab combined with RALOX regimen HAIC in advanced hepatocellular carcinoma.

Recruiting17 enrollment criteria

A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

MelanomaUrothelial Carcinoma4 more

Safety study of RC198 in Subjects with Solid Tumors.

Recruiting69 enrollment criteria

PRE-I-SPY Phase I/Ib Oncology Platform Program

HER2-positive Breast CancerMetastatic Cancer17 more

I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.

Recruiting39 enrollment criteria

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Non-Small Cell Lung CancerRenal Cell Carcinoma2 more

This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.

Recruiting12 enrollment criteria

Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

Hepatocellular carcinoma is one of the most intractable primary malignancies in the hepatobiliary and pancreatic tract with a poor overall survival worldwide. Unfortunately, the vast majority of hepatocellular carcinoma patients suffer from advanced unresectable or metastatic disease at diagnosis. Currently targeted therapy alone, or in combination with anti-vascular endothelial growth factor antagonist, is the standard first-line treatment for metastatic hepatocellular carcinoma. On the other hand, there is growing evidence suggesting that radiation therapy (external or internal) with or without immune checkpoint inhibitors can produce or even augment abscopal effect in which the tumours away from the radiation field also show significant tumour shrinkage. The underlying mechanism of eliciting abscopal effect includes the increased antigen presentation by the myeloid cells within the tumour stroma leading to enhanced tumour cell killing. Previous case reports showed that radiation therapy alone can induce abscopal effect in mice and human models. However, a robust and concrete evidence of abscopal effect with combinational immune checkpoint inhibitors and radioembolisation or external radiation therapy in hepatocellular carcinoma is still lacking. This study investigates the efficacy and safety of immune checkpoint inhibitors and radioembolisation as first-line treatment for previously untreated metastatic hepatocellular carcinoma.

Recruiting34 enrollment criteria

Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for...

Esophageal Squamous Cell CarcinomaChemotherapy Effect1 more

This study is a phase III, multicenter, prospective randomized controlled clinical study comparing the efficacy of non-surgical esophageal squamous cell carcinoma with radical chemoradiotherapy and radical chemoradiotherapy combined with consolidation chemotherapy. The survival time and side effects of patients were observed and compared.

Recruiting23 enrollment criteria

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients...

Urothelial Carcinoma

This trial is an open, phase II clinical study. The study is divided into two parts: A and B, and the part A evaluate the safety and tolerability of AZD4547 combined with Tislelizumab in patients with locally advanced or metastatic urothelial cancer, determine the recommended dose of midoral AZD4547 combined with Tislelizumab in a Chinese patient population. Part B study will evaluate the efficacy of this recommended dose combined with Tislelizumab in patients with locally advanced or metastatic urothelial cancer with FGFR2 / 3 alterations , and will also further evaluate the safety, tolerability, and PK and PD characteristics of AZD4547 in combination with Tislelizumab.

Recruiting28 enrollment criteria

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

Invasive Ductal Breast CarcinomaInvasive Ductal Breast Carcinoma Stage IV13 more

The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many immune cells are able to attack and kill tumor cells (immune infiltration).

Recruiting12 enrollment criteria
1234...783

Need Help? Contact our team!


We'll reach out to this number within 24 hrs